Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes

Context: Dipeptidyl peptidase 4 (DPP-4) inhibitors are proposed to lower blood glucose in type 2 diabetes mellitus (T2DM) by prolonging the activity of the circulating incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1). Consistent with this mechanism of...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: D'Alessio, David A., Denney, Amanda M., Hermiller, Linda M., Prigeon, Ronald L., Martin, Julie M., Tharp, William G., Saylan, Monica Liqueros, He, YanLing, Dunning, Beth E., Foley, James E., Pratley, Richard E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: The Endocrine Society 2009
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2630874/
https://ncbi.nlm.nih.gov/pubmed/18957505
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2008-1135
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk